RGNX — REGENXBIO Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1590877 ·
Last close
$8.06
Market Cap
$531.74M
52W High
$15.88
52W Low
$5.88
ADV30
1,571,984
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 108,019,000 | 106,977,000 | 29,263,000 | 22,709,000 | 386,618,000 | 36,487,000 | 314,853,000 |
| Mar 2026 | 6,393,000 | -4,681,000 | -83,362,000 | -90,051,000 | 341,894,000 | 15,229,000 | 320,812,000 |
| Dec 2025 | 30,337,000 | 24,409,000 | -57,636,000 | -67,149,000 | 453,032,000 | 34,466,000 | 350,299,000 |
| Sep 2025 | 29,733,000 | 24,008,000 | -52,411,000 | -61,941,000 | 525,203,000 | 58,802,000 | 363,751,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-246,674,000
Investing CF
$216,338,000
Financing CF
$-12,735,000
CapEx
$-2,994,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.79
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,193,369,000
Inventory
—
Receivables
$107,102,000
ST Investments
$69,030,000
EBIT TTM
$-154,486,000
Pretax Income TTM
$-196,432,000
Interest Exp TTM
$41,946,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$174,482,000
EBITDA
$-148,776,992
Free Cash Flow
$-184,263,504
Enterprise Value
$676,681,280
Total Cash
$105,517,000
Total Debt
$250,462,000
Shares Out
66,013,192
Trailing EPS
$-2.84
Book Value
$1.32
ROE
-137.6%
ROA
-21.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 170,441,000 | -161,198,000 | -193,878,000 | 453,032,000 | 350,299,000 | — | -123,963,000 |
| Dec 2024 | 83,328,000 | -231,245,000 | -227,102,000 | 465,989,000 | 206,338,000 | — | -173,125,000 |
| Dec 2023 | 90,242,000 | -268,128,000 | -263,494,000 | 573,970,000 | 262,228,000 | — | -218,407,000 |
| Dec 2022 | 112,724,000 | -262,876,000 | -280,321,000 | 833,268,000 | 317,073,000 | — | -207,488,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.00
Max Pain — expiry 2026-09-18
max pain strike: $10.00 · spot: $8.85 · call oi: 1,056 · put oi: 1,731
Expected Move to 2026-09-18:
±$1.32
(14.97%) —
implied range
$7.53 –
$10.18
· ATM straddle on $9.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CABA | Cabaletta Bio, Inc. | $525.59M | $3.10 | — |
| KYTX | Kyverna Therapeutics, Inc. | $509.59M | $8.24 | — |
| CCCC | C4 Therapeutics, Inc. | $504.40M | $4.10 | — |
| ARTV | Artiva Biotherapeutics, Inc. | $563.21M | $11.52 | — |
| PRME | Prime Medicine, Inc. | $589.47M | $3.25 | — |
News headlines (Yahoo Finance, 1h cache)
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
2026-08-25 11:05 · Yahoo
Regenxbio’s RGX-121 Setback Carries A Potential Cash Risk, Warns Clear Street
2026-08-25 10:50 · Yahoo
RGNX Stock On Track For Worst Day In Over Three Months — BofA Says Buy Despite ‘Disappointing’ FDA Hold On Gene Therapy
2026-08-24 19:18 · Yahoo
Why Regenxbio Halted Its Gene Therapy Trial—and Why the Stock Is Tumbling
2026-08-24 14:18 · Yahoo
Why Did RGNX Stock Crash Today?
2026-08-24 13:02 · Yahoo
REGENXBIO Shares Plunge After FDA Places Clinical Hold on RGX-121
2026-08-24 12:45 · Yahoo
Safety concerns spur FDA to again halt testing of Regenxbio gene therapy
2026-08-24 11:55 · Yahoo
REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
2026-08-24 11:05 · Yahoo
REGENXBIO Q2 Earnings Call Highlights
2026-08-07 11:03 · Yahoo
REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
2026-08-06 11:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.